These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

147 related articles for article (PubMed ID: 25609987)

  • 1. End-stage renal disease in autosomal dominant polycystic kidney disease: a comparison of dialysis-related utilization and costs with other chronic kidney diseases.
    Brunelli SM; Blanchette CM; Claxton AJ; Roy D; Rossetti S; Gutierrez B
    Clinicoecon Outcomes Res; 2015; 7():65-72. PubMed ID: 25609987
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Hospital-based inpatient resource utilization associated with autosomal dominant polycystic kidney disease in the US.
    Blanchette CM; Craver C; Belk KW; Lubeck DP; Rossetti S; Gutierrez B
    J Med Econ; 2015 Apr; 18(4):303-11. PubMed ID: 25372357
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Healthcare Resource Utilization and Costs Associated with Autosomal Dominant Polycystic Kidney Disease.
    Blanchette CM; Iorga ŞR; Altan A; Seare JG; Fan Y; Rossetti S; Gutierrez B
    J Health Econ Outcomes Res; 2014; 2(1):63-74. PubMed ID: 37664083
    [No Abstract]   [Full Text] [Related]  

  • 4. ESRD from autosomal dominant polycystic kidney disease in the United States, 2001-2010.
    Reule S; Sexton DJ; Solid CA; Chen SC; Collins AJ; Foley RN
    Am J Kidney Dis; 2014 Oct; 64(4):592-9. PubMed ID: 25134777
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Excess healthcare costs in patients with autosomal dominant polycystic kidney disease by renal dysfunction stage.
    Gagnon-Sanschagrin P; Liang Y; Sanon M; Oberdhan D; Guérin A; Cloutier M
    J Med Econ; 2021; 24(1):193-201. PubMed ID: 33464936
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Mortality risk in patients with autosomal dominant polycystic kidney disease.
    Mladsi D; Zhou X; Mader G; Sanon M; Wang J; Barnett C; Willey C; Seliger S
    BMC Nephrol; 2024 Feb; 25(1):56. PubMed ID: 38365638
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Medical resource utilization and costs associated with autosomal dominant polycystic kidney disease in the USA: a retrospective matched cohort analysis of private insurer data.
    Knight T; Schaefer C; Krasa H; Oberdhan D; Chapman A; Perrone RD
    Clinicoecon Outcomes Res; 2015; 7():123-32. PubMed ID: 25759590
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Is CAPD a viable option among ADPKD with end stage renal disease population in India? Its outcomes and economics.
    Kaul A; Dharshan R; Bhadhuaria D; Prasad N; Gupta A; Sharma RK
    Saudi J Kidney Dis Transpl; 2015 Sep; 26(5):906-11. PubMed ID: 26354561
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Radiographic Imaging in Autosomal Dominant Polycystic Kidney Disease: A Claims Analysis.
    Sanon Aigbogun M; Stellhorn RA; Pao CS; Seliger SL
    Int J Nephrol Renovasc Dis; 2021; 14():133-142. PubMed ID: 33994802
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A model to predict disease progression in patients with autosomal dominant polycystic kidney disease (ADPKD): the ADPKD Outcomes Model.
    McEwan P; Bennett Wilton H; Ong ACM; Ørskov B; Sandford R; Scolari F; Cabrera MV; Walz G; O'Reilly K; Robinson P
    BMC Nephrol; 2018 Feb; 19(1):37. PubMed ID: 29439650
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Management of ESRD in patients with autosomal dominant polycystic kidney disease.
    Alam A; Perrone RD
    Adv Chronic Kidney Dis; 2010 Mar; 17(2):164-72. PubMed ID: 20219619
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Modelling the long-term benefits of tolvaptan therapy on renal function decline in autosomal dominant polycystic kidney disease: an exploratory analysis using the ADPKD outcomes model.
    Bennett H; McEwan P; Hamilton K; O'Reilly K
    BMC Nephrol; 2019 Apr; 20(1):136. PubMed ID: 31014270
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Survival after end-stage renal disease in autosomal dominant polycystic kidney disease: contribution of extrarenal complications to mortality.
    Perrone RD; Ruthazer R; Terrin NC
    Am J Kidney Dis; 2001 Oct; 38(4):777-84. PubMed ID: 11576881
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Epidemiology of patients in England and Wales with autosomal dominant polycystic kidney disease and end-stage renal failure.
    Shaw C; Simms RJ; Pitcher D; Sandford R
    Nephrol Dial Transplant; 2014 Oct; 29(10):1910-8. PubMed ID: 24737444
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The societal economic burden of autosomal dominant polycystic kidney disease in the United States.
    Cloutier M; Manceur AM; Guerin A; Aigbogun MS; Oberdhan D; Gauthier-Loiselle M
    BMC Health Serv Res; 2020 Feb; 20(1):126. PubMed ID: 32070341
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Real-world costs of autosomal dominant polycystic kidney disease in the Nordics.
    Eriksson D; Karlsson L; Eklund O; Dieperink H; Honkanen E; Melin J; Selvig K; Lundberg J
    BMC Health Serv Res; 2017 Aug; 17(1):560. PubMed ID: 28806944
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Risk of intracranial hemorrhage associated with autosomal dominant polycystic kidney disease in patients with end stage renal disease.
    Yoo DJ; Agodoa L; Yuan CM; Abbott KC; Nee R
    BMC Nephrol; 2014 Feb; 15():39. PubMed ID: 24571546
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Renal replacement therapy in autosomal dominant polycystic kidney disease.
    Singh S; Hariharan S
    Nephron; 1991; 57(1):40-4. PubMed ID: 2046814
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Incremental health care resource utilization and expenditures associated with autosomal-dominant polycystic kidney disease.
    Iyer NN; Vendetti NJ; Levy DI; Mardekian J; Mychaskiw MA; Thomas J
    Clinicoecon Outcomes Res; 2018; 10():693-703. PubMed ID: 30464562
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cost-effectiveness of angiotensin-converting enzyme inhibitors versus angiotensin II receptor blockers as first-line treatment in autosomal dominant polycystic kidney disease.
    Clark LA; Whitmire S; Patton S; Clark C; Blanchette CM; Howden R
    J Med Econ; 2017 Jul; 20(7):715-722. PubMed ID: 28332417
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.